CEO Kyle Gano was paid $13,448,935 in fiscal year 2025, ↑ up 57.6% from fiscal year 2024, the 33rd percentile of its disclosed peer group (SEC filing 0000914475-26-000015 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$13,448,935 ↑ Kyle Gano total, FY2025 | 33rd CEO pay percentile vs peers | 49:1 CEO-to-median pay ratio | 93.19% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
NBIX's next annual pay disclosure, estimated April 21, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kyle Gano | $920,000 | $966,000 | $5,750,023 | $5,750,006 | $0 | $0 | $62,906 | $13,448,935 |
| Chief Executive Officer and Director | ||||||||
| Sanjay Keswani | 379,167 | 488,000 | 4,000,120 | 3,999,963 | 0 | 0 | 140,553 | 9,007,803 |
| Chief Medical Officer | ||||||||
| Jude Onyia | 720,520 | 645,000 | 2,999,925 | 3,000,011 | 0 | 0 | 45,313 | 7,410,769 |
| Chief Scientific Officer | ||||||||
| Matthew Abernethy | 725,913 | 526,000 | 2,499,918 | 2,500,036 | 0 | 0 | 60,045 | 6,311,912 |
| Chief Financial Officer | ||||||||
| Eiry Roberts | 731,400 | 530,000 | 2,375,004 | 2,375,029 | 0 | 0 | 61,599 | 6,073,032 |
| Strategic Advisor | ||||||||
| Eric Benevich | 668,690 | 463,000 | 2,349,928 | 2,349,995 | 0 | 0 | 57,334 | 5,888,947 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Kyle Gano | $13,448,935 | $8,535,422 | $5,990,215 | ↑ +4,913,513 |
| Sanjay Keswani | 9,007,803 | — | — | — |
| Jude Onyia | 7,410,769 | 7,035,851 | 7,223,216 | ↑ +374,918 |
| Matthew Abernethy | 6,311,912 | 6,595,201 | 6,057,882 | ↓ −283,289 |
| Eiry Roberts | 6,073,032 | 6,764,318 | 5,873,847 | ↓ −691,286 |
| Eric Benevich | 5,888,947 | 6,306,164 | — | ↓ −417,217 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read NEUROCRINE BIOSCIENCES INC's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper NBIX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the NEUROCRINE BIOSCIENCES INC Peer Teardown Report
$13,448,935 Kyle Gano total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of September 15, 2026 · Source: 0000914475-26-000015 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for NBIX
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order NBIX
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
The list of companies that name NBIX as a peer is temporarily unavailable — recheck shortly.
Get the NEUROCRINE BIOSCIENCES INC Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Christine A. Poon | Independent Director | $483,768 |
| Gary A. Lyons | Independent Director | $470,028 |
| George J. Morrow | Independent Director | $481,018 |
| Johanna Mercier | Independent Director | $469,018 |
| Kevin C. Gorman | Director | $470,037 |
| Leslie V. Norwalk | Independent Director | $478,028 |
| Richard F. Pops | Independent Director | $487,768 |
| Shalini Sharp | Independent Director | $500,278 |
| Stephen A. Sherwin | Independent Director | $493,268 |
| William H. Rastetter | Chair of the Board | $505,018 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Leslie V. Norwalk | Director | 2026-05-12 | D | 3,810 | $155 | $590,601 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-15 | A | 15,000 | 48 | 718,350 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-15 | D | 15,000 | 158 | 2,364,761 | Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-19 | D | 205,088 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-19 | A | 205,088 | 43 | 8,868,005 | Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-19 | D | 245,088 | 154 | 37,824,872 | Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-05-21 | A | 1,659 | 0 | 0 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| Gary A. Lyons | Director | 2026-05-21 | A | 1,659 | 0 | 0 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William H. Rastetter | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-21 | — | 4,977 | — | — | 3 insiders, 3 accrual rows | ||
| Shalini Sharp | Director | 2026-05-21 | A | 1,659 | 0 | 0 | Common | Form 4 ↗ |
| Johanna Mercier | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| George J. Morrow | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| William H. Rastetter | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mercier | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| George J. Morrow | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| David W. Boyer | Chief Corp. Affairs Officer | 2026-05-26 | D | 3,888 | 157 | 609,023 | Common | Form 4 ↗ |
| Johanna Mercier | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-05-27 | A | 2,624 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-27 | — | 2,568 | — | — | 2 insiders, 2 accrual rows | ||
| Stephen A. Sherwin | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shalini Sharp | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-27 | A | 5,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-05-27 | D | 11,000 | 156 | 1,710,865 | Common | Form 4 ↗ |
| William H. Rastetter | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| George J. Morrow | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary A. Lyons | Director | 2026-05-27 | A | 2,624 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-05-27 | D | 11,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-05-27 | A | 11,000 | 85 | 932,140 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-05-29 | D | 2,261 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-05-29 | D | 2,261 | 157 | 354,321 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-05-29 | A | 2,261 | 79 | 178,664 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-01 | D | 11,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-01 | A | 11,000 | 85 | 932,140 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-01 | D | 11,000 | 160 | 1,762,710 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-06-02 | D | 3,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-06-02 | D | 1,733 | 155 | 268,338 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | A | 24,965 | 81 | 2,034,398 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-06-02 | A | 3,212 | 0 | 0 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 24,965 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 3,520 | 159 | 558,236 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 9,521 | 158 | 1,500,663 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 4,216 | 157 | 660,925 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 5,466 | 155 | 849,726 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 14,214 | 155 | 2,200,685 | Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-06-04 | D | 1,250 | 168 | 210,072 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-05 | D | 2,441 | 0 | 0 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 7,883 | 164 | 1,291,291 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 1,843 | 167 | 308,357 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 5,829 | 167 | 970,859 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 6,896 | 166 | 1,143,306 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 2,549 | 164 | 419,156 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | A | 10,000 | 80 | 797,900 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | A | 15,000 | 54 | 804,600 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-26 | — | 200 | — | — | 1 insider, 1 accrual row | ||
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | D | 200 | 170 | 33,913 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | A | 200 | 81 | 16,298 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-29 | D | 1,690 | 171 | 288,676 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-29 | D | 8,110 | 170 | 1,378,903 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-29 | — | 1,690 | — | — | 1 insider, 1 accrual row | ||
| Darin Lippoldt | Chief Legal Officer | 2026-06-29 | D | 8,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-29 | A | 8,110 | 81 | 660,884 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-29 | A | 1,690 | 81 | 137,718 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 3,401 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 3,401 | 179 | 607,305 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | A | 3,401 | 104 | 352,072 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-08 | D | 2,737 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-08 | D | 2,737 | 179 | 488,672 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-08 | A | 2,737 | 104 | 283,334 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-07-09 | D | 10,000 | 180 | 1,796,014 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-09 | D | 8,433 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-09 | D | 8,433 | 179 | 1,507,135 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-09 | A | 8,433 | 104 | 872,984 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-07-09 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-07-09 | A | 10,000 | 81 | 814,900 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-10 | A | 4,367 | 106 | 462,989 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-10 | D | 4,367 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-10 | D | 4,367 | 181 | 790,514 | Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-07-28 | D | 1,250 | 182 | 227,508 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-29 | — | 842 | — | — | 1 insider, 1 accrual row | ||
| Leslie V. Norwalk | Director | 2026-07-29 | A | 842 | 139 | 117,400 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-08-04 | D | 2,409 | 0 | 0 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-09-02 | D | 1,000 | 0 | 0 | Common | Form 4 ↗ |
| Eric Benevich | Chief Commercial Officer | 2026-09-09 | D | 2,154 | 155 | 333,030 | Common | Form 4 ↗ |
| Eric Benevich | Chief Commercial Officer | 2026-09-09 | D | 3,194 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Benevich | Chief Commercial Officer | 2026-09-09 | A | 3,194 | 43 | 138,109 | Common | Form 4 ↗ |
| Matthew Abernethy | Chief Financial Officer | 2026-09-11 | A | 5,020 | 0 | 0 | Common | Form 4 ↗ |
| David W. Boyer | Chief Corp. Affairs Officer | 2026-09-11 | D | 1,936 | 156 | 302,442 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-09-11 | A | 4,483 | 0 | 0 | Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-09-11 | D | 7,839 | 156 | 1,224,609 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-09-11 | D | 1,936 | 156 | 302,442 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-09-11 | A | 3,587 | 0 | 0 | Common | Form 4 ↗ |
| Eric Benevich | Chief Commercial Officer | 2026-09-11 | D | 3,386 | 156 | 528,961 | Common | Form 4 ↗ |
| David W. Boyer | Chief Corp. Affairs Officer | 2026-09-11 | A | 3,587 | 0 | 0 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-09-11 | A | 3,587 | 0 | 0 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-09-11 | D | 2,419 | 156 | 377,896 | Common | Form 4 ↗ |
| Kyle Gano | Director | 2026-09-11 | A | 1,842 | 0 | 0 | Common | Form 4 ↗ |
| Kyle Gano | Director | 2026-09-11 | A | 6,275 | 0 | 0 | Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-09-11 | A | 14,343 | 0 | 0 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-09-11 | D | 2,112 | 156 | 329,937 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-09-11 | D | 2,419 | 156 | 377,896 | Common | Form 4 ↗ |
| Matthew Abernethy | Chief Financial Officer | 2026-09-11 | D | 2,709 | 156 | 423,200 | Common | Form 4 ↗ |
| Eric Benevich | Chief Commercial Officer | 2026-09-11 | A | 6,275 | 0 | 0 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-09-11 | D | 1,936 | 156 | 302,442 | Common | Form 4 ↗ |
| Kyle Gano | Director | 2026-09-11 | D | 994 | 156 | 155,283 | Common | Form 4 ↗ |
| Kyle Gano | Director | 2026-09-11 | D | 3,386 | 156 | 528,961 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-09-11 | A | 3,914 | 0 | 0 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-09-11 | A | 4,483 | 0 | 0 | Common | Form 4 ↗ |
| Matthew Abernethy | Chief Financial Officer | 2026-09-14 | D | 2,311 | 157 | 363,285 | Common | Form 4 ↗ |
| David W. Boyer | Chief Corp. Affairs Officer | 2026-09-14 | D | 826 | 157 | 130,051 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Leslie V. Norwalk | Director | 2026-05-12 | D | 3,810 | $155 | $590,601 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-15 | A | 15,000 | 48 | 718,350 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-15 | D | 15,000 | 158 | 2,364,761 | Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-19 | D | 205,088 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-19 | A | 205,088 | 43 | 8,868,005 | Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-19 | D | 245,088 | 154 | 37,824,872 | Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-05-21 | A | 1,659 | 0 | 0 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| Gary A. Lyons | Director | 2026-05-21 | A | 1,659 | 0 | 0 | Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William H. Rastetter | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| Shalini Sharp | Director | 2026-05-21 | D | 1,659 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shalini Sharp | Director | 2026-05-21 | A | 1,659 | 0 | 0 | Common | Form 4 ↗ |
| Gary A. Lyons | Director | 2026-05-21 | D | 1,659 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mercier | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| George J. Morrow | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-05-21 | D | 1,659 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| William H. Rastetter | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mercier | Director | 2026-05-21 | D | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| George J. Morrow | Director | 2026-05-21 | A | 3,318 | 0 | 0 | Common | Form 4 ↗ |
| David W. Boyer | Chief Corp. Affairs Officer | 2026-05-26 | D | 3,888 | 157 | 609,023 | Common | Form 4 ↗ |
| Johanna Mercier | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-05-27 | A | 2,624 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-05-27 | A | 1,284 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shalini Sharp | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-05-27 | A | 5,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-05-27 | D | 11,000 | 156 | 1,710,865 | Common | Form 4 ↗ |
| William H. Rastetter | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| George J. Morrow | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary A. Lyons | Director | 2026-05-27 | A | 2,624 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard F. Pops | Director | 2026-05-27 | A | 2,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-05-27 | D | 11,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-05-27 | A | 11,000 | 85 | 932,140 | Common | Form 4 ↗ |
| Gary A. Lyons | Director | 2026-05-27 | A | 1,284 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-05-29 | D | 2,261 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-05-29 | D | 2,261 | 157 | 354,321 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-05-29 | A | 2,261 | 79 | 178,664 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-01 | D | 11,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-01 | A | 11,000 | 85 | 932,140 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-01 | D | 11,000 | 160 | 1,762,710 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-06-02 | D | 3,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-06-02 | D | 1,733 | 155 | 268,338 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | A | 24,965 | 81 | 2,034,398 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-06-02 | A | 3,212 | 0 | 0 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 24,965 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 3,520 | 159 | 558,236 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 9,521 | 158 | 1,500,663 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 4,216 | 157 | 660,925 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 5,466 | 155 | 849,726 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-06-02 | D | 14,214 | 155 | 2,200,685 | Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-06-04 | D | 1,250 | 168 | 210,072 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-06-05 | D | 2,441 | 0 | 0 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 7,883 | 164 | 1,291,291 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 1,843 | 167 | 308,357 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 5,829 | 167 | 970,859 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 6,896 | 166 | 1,143,306 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | D | 2,549 | 164 | 419,156 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | A | 10,000 | 80 | 797,900 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-05 | A | 15,000 | 54 | 804,600 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | D | 200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | D | 200 | 170 | 33,913 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-26 | A | 200 | 81 | 16,298 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-29 | D | 1,690 | 171 | 288,676 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-29 | D | 8,110 | 170 | 1,378,903 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-29 | D | 1,690 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-29 | D | 8,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-29 | A | 8,110 | 81 | 660,884 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-06-29 | A | 1,690 | 81 | 137,718 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 3,401 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | D | 3,401 | 179 | 607,305 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-07 | A | 3,401 | 104 | 352,072 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-08 | D | 2,737 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-08 | D | 2,737 | 179 | 488,672 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-08 | A | 2,737 | 104 | 283,334 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-07-09 | D | 10,000 | 180 | 1,796,014 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-09 | D | 8,433 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-09 | D | 8,433 | 179 | 1,507,135 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-09 | A | 8,433 | 104 | 872,984 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-07-09 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-07-09 | A | 10,000 | 81 | 814,900 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-10 | A | 4,367 | 106 | 462,989 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-10 | D | 4,367 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-07-10 | D | 4,367 | 181 | 790,514 | Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-07-28 | D | 1,250 | 182 | 227,508 | Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-07-29 | D | 842 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie V. Norwalk | Director | 2026-07-29 | A | 842 | 139 | 117,400 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-08-04 | D | 2,409 | 0 | 0 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-09-02 | D | 1,000 | 0 | 0 | Common | Form 4 ↗ |
| Eric Benevich | Chief Commercial Officer | 2026-09-09 | D | 2,154 | 155 | 333,030 | Common | Form 4 ↗ |
| Eric Benevich | Chief Commercial Officer | 2026-09-09 | D | 3,194 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Benevich | Chief Commercial Officer | 2026-09-09 | A | 3,194 | 43 | 138,109 | Common | Form 4 ↗ |
| Matthew Abernethy | Chief Financial Officer | 2026-09-11 | A | 5,020 | 0 | 0 | Common | Form 4 ↗ |
| David W. Boyer | Chief Corp. Affairs Officer | 2026-09-11 | D | 1,936 | 156 | 302,442 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-09-11 | A | 4,483 | 0 | 0 | Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-09-11 | D | 7,839 | 156 | 1,224,609 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-09-11 | D | 1,936 | 156 | 302,442 | Common | Form 4 ↗ |
| Jude Onyia | Chief Scientific Officer | 2026-09-11 | A | 3,587 | 0 | 0 | Common | Form 4 ↗ |
| Eric Benevich | Chief Commercial Officer | 2026-09-11 | D | 3,386 | 156 | 528,961 | Common | Form 4 ↗ |
| David W. Boyer | Chief Corp. Affairs Officer | 2026-09-11 | A | 3,587 | 0 | 0 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-09-11 | A | 3,587 | 0 | 0 | Common | Form 4 ↗ |
| Ingrid Delaet | Chief Regulatory Officer | 2026-09-11 | D | 2,419 | 156 | 377,896 | Common | Form 4 ↗ |
| Kyle Gano | Director | 2026-09-11 | A | 1,842 | 0 | 0 | Common | Form 4 ↗ |
| Kyle Gano | Director | 2026-09-11 | A | 6,275 | 0 | 0 | Common | Form 4 ↗ |
| Kevin C. Gorman | Director | 2026-09-11 | A | 14,343 | 0 | 0 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-09-11 | D | 2,112 | 156 | 329,937 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-09-11 | D | 2,419 | 156 | 377,896 | Common | Form 4 ↗ |
| Matthew Abernethy | Chief Financial Officer | 2026-09-11 | D | 2,709 | 156 | 423,200 | Common | Form 4 ↗ |
| Eric Benevich | Chief Commercial Officer | 2026-09-11 | A | 6,275 | 0 | 0 | Common | Form 4 ↗ |
| Julie Cooke | Chief Human Resources Officer | 2026-09-11 | D | 1,936 | 156 | 302,442 | Common | Form 4 ↗ |
| Kyle Gano | Director | 2026-09-11 | D | 994 | 156 | 155,283 | Common | Form 4 ↗ |
| Kyle Gano | Director | 2026-09-11 | D | 3,386 | 156 | 528,961 | Common | Form 4 ↗ |
| Sanjay Keswani | Chief Medical Officer | 2026-09-11 | A | 3,914 | 0 | 0 | Common | Form 4 ↗ |
| Darin Lippoldt | Chief Legal Officer | 2026-09-11 | A | 4,483 | 0 | 0 | Common | Form 4 ↗ |
| Matthew Abernethy | Chief Financial Officer | 2026-09-14 | D | 2,311 | 157 | 363,285 | Common | Form 4 ↗ |
| David W. Boyer | Chief Corp. Affairs Officer | 2026-09-14 | D | 826 | 157 | 130,051 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Sanjay Keswani | PSU | 2025-03-06 | 6,262 | 7,828 | — | 9,785 | $975,056 |
| Matthew Abernethy | PSU | 2025-01-30 | 12,800 | 19,202 | — | 25,602 | 1,499,904 |
| Matthew Abernethy | RSU | 2025-01-30 | — | — | 8,534 | — | 1,000,014 |
| Eric Benevich | RSU | 2025-01-30 | — | — | 8,022 | — | 940,018 |
| Jude Onyia | RSU | 2025-01-30 | — | — | 10,241 | — | 1,200,040 |
| Sanjay Keswani | RSU | 2025-03-06 | — | — | 12,846 | — | 1,600,098 |
| Kyle Gano | PSU | 2025-01-30 | 29,442 | 44,162 | — | 58,884 | 3,450,014 |
| Eiry Roberts | RSU | 2025-01-30 | — | — | 8,108 | — | 950,095 |
| Sanjay Keswani | PSU | 2025-03-06 | 11,440 | 17,160 | — | 22,880 | 1,424,966 |
| Eric Benevich | PSU | 2025-01-30 | 12,032 | 18,050 | — | 24,066 | 1,409,910 |
| Kyle Gano | RSU | 2025-01-30 | — | — | 19,628 | — | 2,300,009 |
| Eiry Roberts | PSU | 2025-01-30 | 12,160 | 18,242 | — | 24,322 | 1,424,909 |
| Jude Onyia | PSU | 2025-01-30 | 15,360 | 23,042 | — | 30,722 | 1,799,885 |
| Sanjay Keswani | OPTION | 2025-03-06 | — | — | 70,101 | — | 3,999,963 |
| Eric Benevich | OPTION | 2025-01-30 | — | — | 42,805 | — | 2,349,995 |
| Kyle Gano | OPTION | 2025-01-30 | — | — | 104,736 | — | 5,750,006 |
| Matthew Abernethy | OPTION | 2025-01-30 | — | — | 45,538 | — | 2,500,036 |
| Jude Onyia | OPTION | 2025-01-30 | — | — | 54,645 | — | 3,000,011 |
| Eiry Roberts | OPTION | 2025-01-30 | — | — | 43,261 | — | 2,375,029 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Sanjay Keswani | $1,600,098 | $2,400,022 | $3,999,963 | 30.0% |
| Matthew Abernethy | 1,000,014 | 1,499,904 | 2,500,036 | 30.0% |
| Eric Benevich | 940,018 | 1,409,910 | 2,349,995 | 30.0% |
| Jude Onyia | 1,200,040 | 1,799,885 | 3,000,011 | 30.0% |
| Kyle Gano | 2,300,009 | 3,450,014 | 5,750,006 | 30.0% |
| Eiry Roberts | 950,095 | 1,424,909 | 2,375,029 | 30.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Eiry Roberts | RSU | 4,115 | — | $583,630 |
| Jude Onyia | Option | 29,287 | 133.84 | — |
| Eiry Roberts | RSU | 16,613 | — | 2,356,222 |
| Kyle Gano | RSU | 12,550 | — | 1,779,967 |
| Kyle Gano | RSU | 9,968 | — | 1,413,761 |
| Kyle Gano | RSU | 6,725 | — | 953,807 |
| Matthew Abernethy | RSU | 6,725 | — | 953,807 |
| Eric Benevich | RSU | 4,166 | — | 590,864 |
| Matthew Abernethy | Option | 18,605 | 103.52 | — |
| Eiry Roberts | RSU | 2,769 | — | 392,727 |
| Sanjay Keswani | PSU | 7,828 | — | 1,110,245 |
| Kyle Gano | RSU | 5,132 | — | 727,872 |
| Matthew Abernethy | RSU | 5,132 | — | 727,872 |
| Eiry Roberts | RSU | 4,227 | — | 599,515 |
| Sanjay Keswani | Option | 70,101 | 124.56 | — |
| Jude Onyia | Option | 43,261 | 117.18 | — |
| Eiry Roberts | Option | 34,248 | 117.18 | — |
| Jude Onyia | Option | 19,699 | 103.52 | — |
| Kyle Gano | Option | 24,406 | 133.84 | — |
| Eiry Roberts | Option | 1,571 | 79.02 | — |
| Eric Benevich | RSU | 5,885 | — | 834,670 |
| Kyle Gano | PSU | 29,442 | — | 4,175,759 |
| Kyle Gano | RSU | 19,628 | — | 2,783,839 |
| Jude Onyia | PSU | 15,361 | — | 2,178,651 |
| Sanjay Keswani | RSU | 12,846 | — | 1,821,948 |
| Eric Benevich | PSU | 12,033 | — | 1,706,641 |
| Sanjay Keswani | RSU | 11,441 | — | 1,622,677 |
| Jude Onyia | RSU | 10,241 | — | 1,452,481 |
| Matthew Abernethy | RSU | 8,534 | — | 1,210,377 |
| Eiry Roberts | RSU | 8,108 | — | 1,149,958 |
| Eric Benevich | RSU | 8,022 | — | 1,137,760 |
| Eric Benevich | Option | 15,103 | 103.52 | — |
| Kyle Gano | PSU | 3,683 | — | 522,360 |
| Eiry Roberts | Option | 12,203 | 133.84 | — |
| Matthew Abernethy | RSU | 2,437 | — | 345,640 |
| Kyle Gano | Option | 82,916 | 117.18 | — |
| Matthew Abernethy | RSU | 10,040 | — | 1,423,973 |
| Kyle Gano | RSU | 2,927 | — | 415,136 |
| Jude Onyia | RSU | 238 | — | 33,756 |
| Jude Onyia | Option | 135 | 79.02 | — |
| Eric Benevich | Option | 33,887 | 117.18 | — |
| Eric Benevich | RSU | 16,613 | — | 2,356,222 |
| Kyle Gano | Option | 1,661 | 79.02 | — |
| Jude Onyia | RSU | 8,070 | — | 1,144,568 |
| Matthew Abernethy | RSU | 9,968 | — | 1,413,761 |
| Eric Benevich | RSU | 12,550 | — | 1,779,967 |
| Kyle Gano | Option | 18,605 | 103.52 | — |
| Jude Onyia | RSU | 7,172 | — | 1,017,205 |
| Matthew Abernethy | Option | 24,406 | 133.84 | — |
| Eiry Roberts | RSU | 7,172 | — | 1,017,205 |
| Kyle Gano | RSU | 1,842 | — | 261,251 |
| Matthew Abernethy | Option | 1,383 | 79.02 | — |
| Eric Benevich | Option | 1,302 | 79.02 | — |
| Jude Onyia | RSU | 19,935 | — | 2,827,381 |
| Matthew Abernethy | PSU | 12,801 | — | 1,815,566 |
| Eiry Roberts | PSU | 12,161 | — | 1,724,795 |
| Matthew Abernethy | Option | 36,051 | 117.18 | — |
| Eiry Roberts | Option | 15,322 | 103.52 | — |
| Jude Onyia | RSU | 5,434 | — | 770,704 |
| Eric Benevich | Option | 21,356 | 133.84 | — |
| Eiry Roberts | RSU | 3,363 | — | 476,974 |
| Kyle Gano | Option | 9,730 | 122.21 | — |
| Eiry Roberts | Option | 15,042 | 136.69 | — |
| Eric Benevich | RSU | 2,294 | — | 325,358 |
We believe that in order to create value for our stockholders, it is critical to attract, motivate and retain key executive officer talent by providing competitive compensation packages. Our compensation philosophy for executive officers provides that cash compensation should be structured such that at least one-third of each executive officer's target total cash compensation, consisting of base salary and target cash incentives, is at risk and dependent upon the Company's achievement of specific corporate goals that drive stockholder value.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Frederic W. Cook & Co., Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-27 | 78,993,894 | 5,669,155 | 103,231 | 93.19% | Passed |
| 2025 | 2025-05-21 | 77,981,925 | 6,070,336 | 1,676,512 | 90.96% | Passed |
| 2024 | 2024-05-22 | 80,281,842 | 4,276,395 | 1,106,972 | 93.72% | Passed |
| 2023 | 2023-05-17 | 75,903,905 | 5,557,583 | 61,094 | 93.11% | Passed |
| 2022 | 2022-05-18 | 76,665,649 | 5,934,421 | 43,078 | 92.77% | Passed |
| 2021 | 2021-05-19 | 77,232,378 | 2,952,915 | 95,463 | 96.2% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-27 | 93.19%a |
| 2025 | 2025-05-21 | 90.96%b |
| 2024 | 2024-05-22 | 93.72%c |
a. Approved under the standard stated in the filing — “Accordingly, an abstention will have the effect of a negative vote for each item.”.
b. Approved under the standard stated in the filing — “Accordingly, an abstention will have the effect of a negative vote for each item.”.
c. Approved under the standard stated in the filing — “Accordingly, an abstention will have the effect of a negative vote for each item.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 49 : 1 |
|---|---|
| CEO total compensation | $13,448,935 |
| Median employee compensation | $273,341 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| William H. RastetterIndependent · Board Chair · Science and Medical Technology · Not standing for re-election | $105,000 | $400,018 | — | $0 | $0 | $505,018 |
| Shalini SharpIndependent · Audit (Chair) · Compensation · Not standing for re-election | 100,250 | 200,009 | 200,019 | 0 | 0 | 500,278 |
| Stephen A. SherwinIndependent · Audit · Science and Medical Technology (Chair) · Not standing for re-election | 93,250 | 400,018 | — | 0 | 0 | 493,268 |
| Richard F. PopsIndependent · Compensation (Chair) · Nominating/Corporate Governance · Science and Medical Technology · Not standing for re-election | 87,750 | 400,018 | — | 0 | 0 | 487,768 |
| Christine A. PoonIndependent · Audit · Nominating/Corporate Governance · Not standing for re-election | 83,750 | 400,018 | — | 0 | 0 | 483,768 |
| George J. MorrowIndependent · Compensation · Nominating/Corporate Governance · Not standing for re-election | 81,000 | 400,018 | — | 0 | 0 | 481,018 |
| Leslie V. NorwalkIndependent · Nominating/Corporate Governance (Chair) · Not standing for re-election | 78,000 | 200,009 | 200,019 | 0 | 0 | 478,028 |
| Kevin C. GormanNot independent · Science and Medical Technology | 70,000 | — | 400,037 | 0 | 0 | 470,037 |
| Gary A. LyonsIndependent · Science and Medical Technology | 70,000 | 200,009 | 200,019 | 0 | 0 | 470,028 |
| Johanna MercierIndependent · Nominating/Corporate Governance | 69,000 | 400,018 | — | 0 | 0 | 469,018 |
| Kyle W. GanoEmployee director · Not standing for re-election | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | $400,018 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 18,000 |
| Stock ownership guideline | $180,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $838,000 |
| Equity awards (grant-date value) | $3,000,135 |
| All other compensation | $0 |
| Total cost of the board | $3,838,135 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies NEUROCRINE BIOSCIENCES INC names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including NEUROCRINE BIOSCIENCES INC.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | Biogen Inc. | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 4 | Biomarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 5 | Moderna, Inc. | 2025 | Stéphane Bancel | 1,677,739 | 6,897,455 | 6,897,425 | 4,302,360 | 19,932,217 |
| 6 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 7 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 8 | BeOne Medicines Ltd. | 2025 | John Oyler | 1,133,000 | 11,249,615 | 3,749,967 | 1,676,840 | 17,943,521 |
| 9 | Organon & Co. | 2025 | Kevin Ali | 1,088,462 | 10,251,989 | 3,249,999 | 0 | 15,813,296 |
| 10 | Alnylam Pharmaceuticals, Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 11 | NEUROCRINE BIOSCIENCES INC | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 12 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 13 | Ultragenyx Pharmaceutical Inc | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 14 | ACADIA Pharmaceuticals, Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 15 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 16 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| — | argenx SE | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| ACADIA Pharmaceuticals, Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Alkermes plc | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Alnylam Pharmaceuticals, Inc. | 200% | PSU 50 · RSU 25 · Option 25 | No | Pay Governance |
| argenx SE | not disclosed | not disclosed | not disclosed | not disclosed |
| BeOne Medicines Ltd. | 148% | PSU 50 · Options 25 · RSU 25 | No | Pay Governance |
| Biogen Inc. | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| Biomarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Incyte Corporation | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Moderna, Inc. | 170% | PSU 50 · Options 50 | No | Pay Governance LLC |
| Organon & Co. | 72% | PSU 50 · RSU 25 · Options 25 | Yes — Three-Year Relative TSR | Korn Ferry |
| Sarepta Therapeutics, Inc. | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| Ultragenyx Pharmaceutical Inc | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| United Therapeutics Corporation | 221% | PSO 50 · PSU 50 | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Kyle Gano | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Summary Compensation Table”. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 2 | Section 01, Sanjay Keswani | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Summary Compensation Table”. As printed: 9,007,803. Filing ↗machine: t50 · r10 · c7 · span 859729–859738 |
| 3 | Section 01, Jude Onyia | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Summary Compensation Table”. As printed: 7,410,769. Filing ↗machine: t50 · r14 · c7 · span 866156–866165 |
| 4 | Section 01, Matthew Abernethy | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Summary Compensation Table”. As printed: 6,311,912. Filing ↗machine: t50 · r7 · c7 · span 853754–853763 |
| 5 | Section 01, Eiry Roberts | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Summary Compensation Table”. As printed: 6,073,032. Filing ↗ |
| 6 | Section 01, Eric Benevich | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Summary Compensation Table”. As printed: 5,888,947. Filing ↗machine: t50 · r9 · c7 · span 857757–857766 |
| 7 | Section 03, Sanjay Keswani PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r15 · c5 · span 922606–922611 |
| 8 | Section 03, Matthew Abernethy PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r7 · c7 · span 909050–909056 |
| 9 | Section 03, Matthew Abernethy RSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r6 · c7 · span 907406–907411 |
| 10 | Section 03, Eric Benevich RSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t45 · r5 · c12 · span 779670–779675 |
| 11 | Section 03, Jude Onyia RSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t45 · r6 · c12 · span 783310–783316 |
| 12 | Section 03, Sanjay Keswani RSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r12 · c7 · span 917903–917909 |
| 13 | Section 03, Kyle Gano PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r4 · c7 · span 903792–903798 |
| 14 | Section 03, Eiry Roberts RSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r19 · c7 · span 930385–930390 |
| 15 | Section 03, Sanjay Keswani PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r13 · c7 · span 919546–919552 |
| 16 | Section 03, Eric Benevich PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r10 · c7 · span 914298–914304 |
| 17 | Section 03, Kyle Gano RSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r3 · c7 · span 901742–901748 |
| 18 | Section 03, Eiry Roberts PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r20 · c7 · span 932027–932033 |
| 19 | Section 03, Jude Onyia PSU | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r17 · c7 · span 926772–926778 |
| 20 | Section 03, Sanjay Keswani OPTION | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r14 · c8 · span 921126–921132 |
| 21 | Section 03, Eric Benevich OPTION | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t45 · r5 · c6 · span 778763–778769 |
| 22 | Section 03, Kyle Gano OPTION | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r5 · c8 · span 905774–905781 |
| 23 | Section 03, Matthew Abernethy OPTION | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r8 · c8 · span 910632–910638 |
| 24 | Section 03, Jude Onyia OPTION | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t45 · r6 · c6 · span 782401–782407 |
| 25 | Section 03, Eiry Roberts OPTION | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Grants of Plan-Based Awards During 202” · grants of plan-based awards table. Filing ↗machine: t54 · r21 · c8 · span 933609–933615 |
| 26 | Section 07, pay ratio | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “CEO Pay Ratio”. As printed: 49 : 1. Filing ↗machine: span 1221176–1221183 |
| 27 | Section 08, William H. Rastetter | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 505,018. Filing ↗machine: t70 · r2 · c8 · span 1312840–1313107 |
| 28 | Section 08, Shalini Sharp | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 500,278. Filing ↗machine: t70 · r10 · c8 · span 1325026–1325267 |
| 29 | Section 08, Stephen A. Sherwin | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 493,268. Filing ↗machine: t70 · r11 · c8 · span 1326554–1326795 |
| 30 | Section 08, Richard F. Pops | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 487,768. Filing ↗machine: t70 · r9 · c8 · span 1323512–1323753 |
| 31 | Section 08, Christine A. Poon | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 483,768. Filing ↗machine: t70 · r8 · c8 · span 1321998–1322239 |
| 32 | Section 08, George J. Morrow | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 481,018. Filing ↗machine: t70 · r6 · c8 · span 1318936–1319177 |
| 33 | Section 08, Leslie V. Norwalk | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 478,028. Filing ↗machine: t70 · r7 · c8 · span 1320453–1320694 |
| 34 | Section 08, Kevin C. Gorman | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 470,037. Filing ↗machine: t70 · r3 · c8 · span 1314397–1314638 |
| 35 | Section 08, Gary A. Lyons | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 470,028. Filing ↗machine: t70 · r4 · c8 · span 1315909–1316150 |
| 36 | Section 08, Johanna Mercier | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 469,018. Filing ↗machine: t70 · r5 · c8 · span 1317422–1317663 |
| 37 | Section 08, Kyle W. Gano | DEF 14A | 2026-04-15 | 0000914475-26-000015 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 38 | Section 02, Leslie V. Norwalk 2026-05-12 | Form 4 | 2026-05-14 | 0001533568-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Richard F. Pops 2026-05-15 | Form 4 | 2026-05-18 | 0000914475-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Richard F. Pops 2026-05-15 | Form 4 | 2026-05-18 | 0000914475-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Richard F. Pops 2026-05-15 | Form 4 | 2026-05-18 | 0000914475-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Kevin C. Gorman 2026-05-19 | Form 4 | 2026-05-21 | 0001201096-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Kevin C. Gorman 2026-05-19 | Form 4 | 2026-05-21 | 0001201096-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Kevin C. Gorman 2026-05-19 | Form 4 | 2026-05-21 | 0001201096-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Leslie V. Norwalk 2026-05-21 | Form 4 | 2026-05-21 | 0001533568-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Christine A. Poon 2026-05-21 | Form 4 | 2026-05-21 | 0001189014-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Gary A. Lyons 2026-05-21 | Form 4 | 2026-05-21 | 0001123343-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Richard F. Pops 2026-05-21 | Form 4 | 2026-05-21 | 0001126490-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, William H. Rastetter 2026-05-21 | Form 4 | 2026-05-21 | 0001205903-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Shalini Sharp 2026-05-21 | Form 4 | 2026-05-21 | 0001377202-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Shalini Sharp 2026-05-21 | Form 4 | 2026-05-21 | 0001377202-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Gary A. Lyons 2026-05-21 | Form 4 | 2026-05-21 | 0001123343-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Johanna Mercier 2026-05-21 | Form 4 | 2026-05-21 | 0001782135-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, George J. Morrow 2026-05-21 | Form 4 | 2026-05-21 | 0001068754-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Leslie V. Norwalk 2026-05-21 | Form 4 | 2026-05-21 | 0001533568-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Christine A. Poon 2026-05-21 | Form 4 | 2026-05-21 | 0001189014-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Richard F. Pops 2026-05-21 | Form 4 | 2026-05-21 | 0001126490-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, William H. Rastetter 2026-05-21 | Form 4 | 2026-05-21 | 0001205903-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Stephen A. Sherwin 2026-05-21 | Form 4 | 2026-05-21 | 0001079462-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Johanna Mercier 2026-05-21 | Form 4 | 2026-05-21 | 0001782135-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Stephen A. Sherwin 2026-05-21 | Form 4 | 2026-05-21 | 0001079462-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, George J. Morrow 2026-05-21 | Form 4 | 2026-05-21 | 0001068754-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, David W. Boyer 2026-05-26 | Form 4 | 2026-05-28 | 0001909817-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Johanna Mercier 2026-05-27 | Form 4 | 2026-05-29 | 0001782135-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Leslie V. Norwalk 2026-05-27 | Form 4 | 2026-05-29 | 0001533568-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Leslie V. Norwalk 2026-05-27 | Form 4 | 2026-05-29 | 0001533568-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Stephen A. Sherwin 2026-05-27 | Form 4 | 2026-05-29 | 0001079462-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Shalini Sharp 2026-05-27 | Form 4 | 2026-05-29 | 0001377202-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Christine A. Poon 2026-05-27 | Form 4 | 2026-05-29 | 0001189014-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Kevin C. Gorman 2026-05-27 | Form 4 | 2026-05-29 | 0001201096-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Jude Onyia 2026-05-27 | Form 4 | 2026-05-29 | 0001894425-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, William H. Rastetter 2026-05-27 | Form 4 | 2026-05-29 | 0001205903-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, George J. Morrow 2026-05-27 | Form 4 | 2026-05-29 | 0001068754-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Gary A. Lyons 2026-05-27 | Form 4 | 2026-05-29 | 0001123343-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Richard F. Pops 2026-05-27 | Form 4 | 2026-05-29 | 0001126490-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Jude Onyia 2026-05-27 | Form 4 | 2026-05-29 | 0001894425-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Jude Onyia 2026-05-27 | Form 4 | 2026-05-29 | 0001894425-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Gary A. Lyons 2026-05-27 | Form 4 | 2026-05-29 | 0001123343-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Ingrid Delaet 2026-05-29 | Form 4 | 2026-06-02 | 0001965808-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Ingrid Delaet 2026-05-29 | Form 4 | 2026-06-02 | 0001965808-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Ingrid Delaet 2026-05-29 | Form 4 | 2026-06-02 | 0001965808-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Jude Onyia 2026-06-01 | Form 4 | 2026-06-02 | 0001894425-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Jude Onyia 2026-06-01 | Form 4 | 2026-06-02 | 0001894425-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Jude Onyia 2026-06-01 | Form 4 | 2026-06-02 | 0001894425-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Sanjay Keswani 2026-06-02 | Form 4 | 2026-06-04 | 0001818524-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Sanjay Keswani 2026-06-02 | Form 4 | 2026-06-04 | 0001818524-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Sanjay Keswani 2026-06-02 | Form 4 | 2026-06-04 | 0001818524-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Julie Cooke 2026-06-02 | Form 4 | 2026-06-04 | 0001776977-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Leslie V. Norwalk 2026-06-04 | Form 4 | 2026-06-08 | 0001533568-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Jude Onyia 2026-06-05 | Form 4 | 2026-06-09 | 0001894425-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Stephen A. Sherwin 2026-06-05 | Form 4 | 2026-06-09 | 0001079462-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Darin Lippoldt 2026-06-26 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Darin Lippoldt 2026-06-26 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Darin Lippoldt 2026-06-26 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Darin Lippoldt 2026-06-29 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Darin Lippoldt 2026-06-29 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Darin Lippoldt 2026-06-29 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Darin Lippoldt 2026-06-29 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Darin Lippoldt 2026-06-29 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Darin Lippoldt 2026-06-29 | Form 4 | 2026-06-30 | 0001504783-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Ingrid Delaet 2026-07-07 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Ingrid Delaet 2026-07-07 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Ingrid Delaet 2026-07-07 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Ingrid Delaet 2026-07-08 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Ingrid Delaet 2026-07-08 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Ingrid Delaet 2026-07-08 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Darin Lippoldt 2026-07-09 | Form 4 | 2026-07-13 | 0001504783-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Ingrid Delaet 2026-07-09 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Ingrid Delaet 2026-07-09 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Ingrid Delaet 2026-07-09 | Form 4 | 2026-07-09 | 0001965808-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Darin Lippoldt 2026-07-09 | Form 4 | 2026-07-13 | 0001504783-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Darin Lippoldt 2026-07-09 | Form 4 | 2026-07-13 | 0001504783-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Ingrid Delaet 2026-07-10 | Form 4 | 2026-07-13 | 0001965808-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Ingrid Delaet 2026-07-10 | Form 4 | 2026-07-13 | 0001965808-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Ingrid Delaet 2026-07-10 | Form 4 | 2026-07-13 | 0001965808-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Leslie V. Norwalk 2026-07-28 | Form 4 | 2026-07-30 | 0001533568-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Leslie V. Norwalk 2026-07-29 | Form 4 | 2026-07-30 | 0001533568-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Leslie V. Norwalk 2026-07-29 | Form 4 | 2026-07-30 | 0001533568-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Jude Onyia 2026-08-04 | Form 4 | 2026-08-05 | 0001894425-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Stephen A. Sherwin 2026-09-02 | Form 4 | 2026-09-03 | 0001079462-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Eric Benevich 2026-09-09 | Form 4 | 2026-09-10 | 0001643653-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Eric Benevich 2026-09-09 | Form 4 | 2026-09-10 | 0001643653-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Eric Benevich 2026-09-09 | Form 4 | 2026-09-10 | 0001643653-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Matthew Abernethy 2026-09-11 | Form 4 | 2026-09-15 | 0001724097-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, David W. Boyer 2026-09-11 | Form 4 | 2026-09-15 | 0001909817-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Ingrid Delaet 2026-09-11 | Form 4 | 2026-09-15 | 0001965808-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Kevin C. Gorman 2026-09-11 | Form 4 | 2026-09-15 | 0001201096-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Jude Onyia 2026-09-11 | Form 4 | 2026-09-15 | 0001894425-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Jude Onyia 2026-09-11 | Form 4 | 2026-09-15 | 0001894425-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Eric Benevich 2026-09-11 | Form 4 | 2026-09-15 | 0001643653-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, David W. Boyer 2026-09-11 | Form 4 | 2026-09-15 | 0001909817-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Julie Cooke 2026-09-11 | Form 4 | 2026-09-15 | 0001776977-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Ingrid Delaet 2026-09-11 | Form 4 | 2026-09-15 | 0001965808-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Kyle Gano 2026-09-11 | Form 4 | 2026-09-15 | 0001567160-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Kyle Gano 2026-09-11 | Form 4 | 2026-09-15 | 0001567160-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Kevin C. Gorman 2026-09-11 | Form 4 | 2026-09-15 | 0001201096-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Sanjay Keswani 2026-09-11 | Form 4 | 2026-09-15 | 0001818524-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Darin Lippoldt 2026-09-11 | Form 4 | 2026-09-15 | 0001504783-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Matthew Abernethy 2026-09-11 | Form 4 | 2026-09-15 | 0001724097-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Eric Benevich 2026-09-11 | Form 4 | 2026-09-15 | 0001643653-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Julie Cooke 2026-09-11 | Form 4 | 2026-09-15 | 0001776977-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Kyle Gano 2026-09-11 | Form 4 | 2026-09-15 | 0001567160-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Kyle Gano 2026-09-11 | Form 4 | 2026-09-15 | 0001567160-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Sanjay Keswani 2026-09-11 | Form 4 | 2026-09-15 | 0001818524-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Darin Lippoldt 2026-09-11 | Form 4 | 2026-09-15 | 0001504783-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, Matthew Abernethy 2026-09-14 | Form 4 | 2026-09-15 | 0001724097-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, David W. Boyer 2026-09-14 | Form 4 | 2026-09-15 | 0001909817-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 06, 2026 vote | Form 8-K | 2026-05-28 | 0000914475-26-000029 | Item 5.07 · say-on-pay result. As reported: 93.19% (votes for as printed: 78,993,894). Filing ↗ |
| 163 | Section 06, 2025 vote | Form 8-K | 2025-05-22 | 0000914475-25-000120 | Item 5.07 · say-on-pay result. As reported: 90.96% (votes for as printed: 77,981,925). Filing ↗ |
| 164 | Section 06, 2024 vote | Form 8-K | 2024-05-23 | 0000914475-24-000140 | Item 5.07 · say-on-pay result. As reported: 93.72% (votes for as printed: 80,281,842). Filing ↗ |
| 165 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 166 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 167 | Section 09b board cost (computed) | Computed | — | — | Cash 838,000 + equity 3,000,135 + all other 0 = 3,838,135, summed across the director compensation table rows.machine: formula: Σ = 3,838,135 |
| 168 | Exelixis, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 169 | Incyte Corporation, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 170 | Biogen Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187303 | CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391 |
| 171 | Biomarin Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in Biomarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 172 | Moderna, Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001308179-26-000081 | CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898 |
| 173 | Jazz Pharmaceuticals plc, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 174 | United Therapeutics Corporation, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 175 | BeOne Medicines Ltd., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-049655 | CEO total compensation as printed in BeOne Medicines Ltd.'s own proxy. As printed: 17,943,521. Filing ↗machine: t180 · r2 · c22 · span 1909011–1909021 |
| 176 | Organon & Co., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177411 | CEO total compensation as printed in Organon & Co.'s own proxy. As printed: 15,813,296. Filing ↗machine: r30 · c18 · span 3922588–3922598 |
| 177 | Alnylam Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001628280-26-023923 | CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701 |
| 178 | NEUROCRINE BIOSCIENCES INC (subject), Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in NEUROCRINE BIOSCIENCES INC's own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 179 | Ionis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗ |
| 180 | Ultragenyx Pharmaceutical Inc, Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical Inc's own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 181 | ACADIA Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals, Inc.'s own proxy. As printed: 8,256,518. Filing ↗ |
| 182 | Alkermes plc, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001193125-26-143977 | CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267 |
| 183 | Sarepta Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404 |
| 184 | Section 10a, ACADIA Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals, Inc. names NEUROCRINE BIOSCIENCES INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 185 | Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-023923 | Alnylam Pharmaceuticals, Inc. names NEUROCRINE BIOSCIENCES INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 186 | Section 10a, Exelixis, Inc. reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis, Inc. names NEUROCRINE BIOSCIENCES INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 187 | Section 10a, Ionis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals, Inc. names NEUROCRINE BIOSCIENCES INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 188 | Section 10a, Organon & Co. reciprocity | DEF 14A | — | 0001193125-26-177411 | Organon & Co.'s most recent proxy was read; its disclosed peer group does not include NEUROCRINE BIOSCIENCES INC. Filing ↗ |
| 189 | Section 10a, Sarepta Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics, Inc. names NEUROCRINE BIOSCIENCES INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 190 | Section 10a, Ultragenyx Pharmaceutical Inc reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical Inc names NEUROCRINE BIOSCIENCES INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 191 | Section 10a, United Therapeutics Corporation reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics Corporation names NEUROCRINE BIOSCIENCES INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 192 | Section 10a, Jazz Pharmaceuticals plc reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals plc names NEUROCRINE BIOSCIENCES INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 193 | Section 10a, Moderna, Inc. reciprocity | DEF 14A | — | 0001308179-26-000081 | Moderna, Inc. names NEUROCRINE BIOSCIENCES INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 194 | Section 10a, Biomarin Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001628280-26-026290 | Biomarin Pharmaceutical Inc. names NEUROCRINE BIOSCIENCES INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 195 | Section 10a, BeOne Medicines Ltd. reciprocity | DEF 14A | — | 0001104659-26-049655 | BeOne Medicines Ltd. names NEUROCRINE BIOSCIENCES INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the NEUROCRINE BIOSCIENCES INC Executive Compensation Report
$1,500